Indian apex court rejects Novartis’ patent plea for Glivec
In 2009, the Switzerland based company filed a special leave petition with the highest judicial forum in India. The petition challenged the rejection of the Glivec beta crystal
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The agreement will leverage Ra Pharmaceuticals’ Extreme Diversity platform for the development of peptide-like molecules with antibody diversity and specificity called Cyclomimetics. Ra Pharmaceuticals co-founder, president and CEO